Angiotensin Receptor Antagonists

Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.

Also Known As:

Angiotensin II Receptor Antagonists; Angiotensin II Receptor Blockers; Angiotensin Receptor Blockers; Antagonist, Angiotensin Receptor; Antagonists, Angiotensin Receptor; Blocker, Angiotensin Receptor; Receptor Antagonist, Angiotensin; Receptor Antagonists, Angiotensin; Receptor Blocker, Angiotensin; Receptor Blockers, Angiotensin; Angiotensin II Receptor Antagonist; Angiotensin II Receptor Blocker; Angiotensin Receptor Antagonist; Angiotensin Receptor Blocker

Networked: 6832 relevant articles (559 outcomes, 1317 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Angiotensin Receptor Antagonists: 6832
      - Angiotensin II Type 1 Receptor Blockers: 717
      - Angiotensin II Type 2 Receptor Blockers: 7

Experts

1.	Fonarow, Gregg C: 50 articles (01/2022 - 01/2002)
2.	Bakris, George L: 41 articles (01/2022 - 01/2002)
3.	McMurray, John J V: 36 articles (01/2022 - 09/2003)
4.	Volpe, Massimo: 29 articles (05/2021 - 04/2002)
5.	Yusuf, Salim: 29 articles (12/2017 - 10/2004)
6.	Solomon, Scott D: 28 articles (01/2022 - 10/2004)
7.	Aronow, Wilbert S: 27 articles (01/2020 - 07/2003)
8.	Hernandez, Adrian F: 24 articles (01/2022 - 12/2008)
9.	Remuzzi, Giuseppe: 23 articles (01/2019 - 12/2002)
10.	White, William B: 23 articles (11/2018 - 06/2005)

Related Diseases

1.	Hypertension (High Blood Pressure) 07/01/2001 - "Angiotensin receptor blockers have proven highly effective in the management of hypertension. " 01/01/2020 - "Angiotensin receptor blockers (ARBs) have proven efficacy in the management of hypertension and related complications. " 01/01/2011 - "Angiotensin II receptor blockers are compounds with a good margin of safety widely used in the treatment of hypertension and their anti-inflammatory and vascular protective effects contribute to reduce renal and cardiovascular failure. " 08/01/2009 - "Recently, we reported that 'pulse' treatment of SHR with high-dose angiotensin receptor blocker (ARB) is effective in causing sustained reduction of already established hypertension, even when the treatment was started after the 'critical period'. " 09/01/2009 - "Angiotensin II receptor blockers have been shown to be effective in treating both hypertension and connected organ damages. "
2.	Heart Failure 11/30/1999 - "Exercise tolerance as a guide to therapeutic efficacy for heart failure : the potential for angiotensin receptor blockers." 08/01/2006 - "It is known that the angiotensin receptor blockers (ARBs) have organ protective effects in patients with heart failure or renal impairment. " 12/01/2006 - "The publication of trials of angiotensin receptor blockers (ARBs) in recent years has led to the need to update the European Society of Cardiology guidelines for the management of chronic heart failure. " 01/01/2021 - "Use of angiotensin receptor blocker is associated with improved 1 year mortality in heart failure with mid-range ejection fraction." 03/12/2001 - "The role of angiotensin receptor blockers in the management of chronic heart failure."
3.	Proteinuria 12/01/2014 - "All the subjects had a marked decrease in proteinuria after angiotensin receptor blocker (ARB) treatment. " 07/01/2003 - "Angiotensin receptor antagonists are effective in reducing proteinuria by an action independent of blood pressure. " 05/01/2006 - "In diabetic patients with advanced nephropathy, the lowering of proteinuria by renin angiotensin system blockers induces an evolution risk reduction, which can be further improved by increasing the dose of angiotensin II receptor antagonist (ARA II). " 03/01/2014 - "Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials." 06/01/2012 - "In the present study, we tested whether the effects of monotherapy with an angiotensin receptor blocker (ARB) to lower proteinuria could be restricted by reduced GFR. "
4.	Diabetic Nephropathies (Diabetic Nephropathy) 01/01/2012 - "The need for an improved treatment for diabetic nephropathy is greatest in patients who do not adequately respond to angiotensin II receptor blockers (ARBs). " 01/01/2018 - "Clinical Efficacy of Jinshuibao Capsules Combined with Angiotensin Receptor Blockers in Patients with Early Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials." 07/01/2012 - "This study aimed to investigate the beneficial effects of angiotensin receptor blockers (ARBs) on markers of endothelial function in patients with early stage of diabetic nephropathy (DN). " 08/01/2005 - "Recent clinical trials have supported the use of angiotensin II receptor antagonists in the treatment of diabetic nephropathy, resulting in the approval of new therapeutic indications in the US and Europe. " 03/01/2004 - "Recent clinical trials have supported the use of angiotensin II receptor antagonists in the treatment of diabetic nephropathy, resulting in the approval of new therapeutic indications in the United States and Europe. "
5.	Stroke (Strokes) 06/01/2007 - "Angiotensin receptor blockers (ARBs) exert a dual influence, which is important in their stroke protective effects. " 06/01/2016 - "Although ACE-Is and angiotensin receptor blockers (ARBs) provide significant benefits in terms of CV events and stroke, mortality remains high. " 12/01/2009 - "Angiotensin receptor blockers were associated with a significant reduction in the risk of stroke than placebo with an OR of 0.91 (0.84 to 0.98). " 12/01/2019 - "This study aimed to re-evaluate the preventive effect of ACEIs on post-stroke AP, compared with that of angiotensin II receptor blockers (ARBs). " 01/01/2013 - "We performed a systematic review of randomized controlled trials that investigated the effects of the angiotensin receptor blockers (ARBs) administered in the acute phase (≤72 hours) of stroke on death and dependency. "

Related Drugs and Biologics

1.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
2.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
3.	Calcium Channel Blockers (Blockers, Calcium Channel)
4.	Antihypertensive Agents (Antihypertensives)
5.	Diuretics
6.	Losartan (Cozaar)
7.	Telmisartan (Micardis)
8.	Neprilysin (Neutral Endopeptidase)
9.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
10.	Angiotensin II

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Secondary Prevention
4.	Transplantation
5.	Implantable Defibrillators (Implantable Cardioverter-Defibrillator)